Top

International Ophthalmology

Published in:

01-03-2019 | Case Report

A case of conjunctival MALT lymphoma: successfully treated with solely extended rituximab therapy

Authors: Hande Celiker, Ebru Toker, Isik Kaygusuz Atagunduz

Published in: International Ophthalmology | Issue 3/2019

Abstract

Purpose

Primary ocular adnexal lymphomas are cured by radiotherapy; however, complications are frequent and relapses may occur. In this case, we aimed to report the efficacy and safety of extended systemic rituximab (anti-CD 20 monoclonal antibody) therapy of conjunctival mucosa-associated lymphoid tissue (MALT) lymphoma.

Methods

In the standard regimen, rituximab is used as four consecutive weekly infusions of 375 mg/m² in patients with low-grade lymphomas. We treated a patient who had bilateral conjunctival MALT lymphoma with rituximab 375 mg/m² intravenously once weekly for 10 weeks as a first-line therapy.

Results

During the examination of the sixth week, we observed partial response of the lesions in both eyes. At the end of the tenth cure, complete remission was achieved. No local or systemic adverse effect was observed. The patient has no signs of recurrence during the 22-months follow-up period.

Conclusion

Extended rituximab therapy may be an effective and well-tolerated first-line treatment option for bilateral conjunctival MALT lymphoma.

Annibali O, Chiodi F, Sarlo C et al (2015) Rituximab as single agent in primary MALT lymphoma of the ocular adnexa. Biomed Res Int 2015:895105. https://doi.org/10.1155/2015/895105 CrossRefPubMedPubMedCentral

Wotherspoon AC, Hardman-Lea S, Isaacson PG (1994) Mucosa-associated lymphoid tissue (MALT) in the human conjunctiva. J Pathol 174:33–37. https://doi.org/10.1002/path.1711740106 CrossRefPubMed

Kiesewetter B, Ferreri AJ, Raderer M (2015) Chemoimmunotherapy for mucosa-associated lymphoid tissue-type lymphoma: a review of the literature. Oncologist 20(8):915–925. https://doi.org/10.1634/theoncologist.2015-0109 CrossRefPubMedPubMedCentral

Kimby E (2005) Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 31:456–473. https://doi.org/10.1016/j.ctrv.2005.05.007 CrossRefPubMed

Freeman C, Berg JW, Cutler SJ (1972) Occurrence and prognosis of extranodal lymphomas. Cancer 29:252–260CrossRefPubMed

Fitzpatrick PJ, Macko S (1984) Lymphoreticular tumors of the orbit. Int J Radiat Oncol Biol Phys 10:333–340CrossRefPubMed

Sasai K, Yamabe H, Dodo Y (2001) Non-Hodgkin’s lymphoma of the ocular adnexa. Acta Oncol 40:485–490CrossRefPubMed

Guffey Johnson J, Terpak LA, Margo CE, Setoodeh R (2016) Extranodal marginal zone B-cell lymphoma of the ocular adnexa. Cancer Control 23:140–149CrossRefPubMed

Harada K, Murakami N, Kitaguchi M et al (2014) Localized ocular adnexal mucosa-associated lymphoid tissue lymphoma treated with radiation therapy: a long-term outcome in 86 patients with 104 treated eyes. Int J Radiat Oncol Biol Phys 88:650–654. https://doi.org/10.1016/j.ijrobp.2013.11.235 CrossRef

10.

Decaudin D, de Cremoux P, Vincent-Salomon A, Dendale R, Rouic LL (2006) Ocular adnexal lymphoma: a review of clinicopathologic features and treatment options. Blood 108:1451–1460. https://doi.org/10.1182/blood-2006-02-005017 CrossRefPubMed

11.

Johnson P, Glennie M (2003) The mechanisms of action of rituximab in the elimination of tumor cells. Semin Oncol 30:3–8. https://doi.org/10.1053/sonc.2003.50025 CrossRefPubMed

12.

Nückel H, Meller D, Steuhl KP, Dührsen U (2004) Anti-CD20 monoclonal antibody therapy in relapsed MALT lymphoma of the conjunctiva. Eur J Haematol 73:258–262. https://doi.org/10.1111/j.1600-0609.2004.00299.x CrossRefPubMed

13.

Tuncer S, Tanyıldız B, Basaran M, Buyukbabani N, Dogan O (2015) Systemic rituximab immunotherapy in the management of primary ocular adnexal lymphoma: single institution experience. Curr Eye Res 40:780–785. https://doi.org/10.3109/02713683.2014.959605 CrossRefPubMed

14.

Ferreri AJ, Ponzoni M, Martinelli G et al (2005) Rituximab in patients with mucosal-associated lymphoid tissue-type lymphoma of the ocular adnexa. Haematologica 90:1578–1579PubMed

15.

Salepci T, Seker M, Kurnaz E et al (2009) Conjunctival malt lymphoma successfully treated with single agent rituximab therapy. Leuk Res 33:e10–e13. https://doi.org/10.1016/j.leukres.2008.05.018 CrossRefPubMed

Title: A case of conjunctival MALT lymphoma: successfully treated with solely extended rituximab therapy
Authors: Hande Celiker
Ebru Toker
Isik Kaygusuz Atagunduz
Publication date: 01-03-2019
Publisher: Springer Netherlands
Published in: International Ophthalmology / Issue 3/2019
Print ISSN: 0165-5701
Electronic ISSN: 1573-2630
DOI: https://doi.org/10.1007/s10792-018-0844-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

A case of conjunctival MALT lymphoma: successfully treated with solely extended rituximab therapy

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2019

Deep blue dot corneal degeneration: confocal characteristics

Impairment of acquired color vision in multiple sclerosis: an early diagnostic sign linked to the greatness of disease

Ocular surface squamous neoplasia in a setting of fungal keratitis: a rare co-occurrence

Corneal perforation after noncontact tonometry in patients with active recurrent herpes simplex keratitis: case report

Association of polymorphisms of complement factor I rs141853578 (G119R) with age-related macular degeneration in Iranian population

Retrobulbar and intraocular blood flow in anterior ischaemic optic neuropathy are linked to the functional impairment